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Abstract
Multiple myeloma is characterized by the accumulation of
clonal malignant plasma cells in the bone marrow, which
stimulates bone destruction by osteoclasts and reduces bone
formation by osteoblasts. In turn, the changed bone microen-
vironment sustains survival of myeloma cells. Therefore, a
challenge for treating multiple myeloma is discovering drugs
targeting not only myeloma cells but also osteoclasts and
osteoblasts. Because resveratrol (trans-3,4V,5-trihydroxystilbene)
is reported to display antitumor activities on a variety
of human cancer cells, we investigated the effects of this
natural compound on myeloma and bone cells. We found that
resveratrol reduces dose-dependently the growth of myeloma
cell lines (RPMI 8226 and OPM-2) by a mechanism involving
cell apoptosis. In cultures of human primary monocytes,
resveratrol inhibits dose-dependently receptor activator of
nuclear factor-KB (NF-KB) ligand–induced formation of
tartrate-resistant acid phosphatase (TRACP)–positive multi-
nucleated cells, TRACP activity in the medium, up-regulation
of cathepsin K gene expression, and bone resorption. These
inhibitions are associated with a down-regulation of RANK
expression at both mRNA and cell surface protein levels and a
decrease of NFATc1 stimulation and NF-KB nuclear translo-
cation, whereas the gene expression of c-fms, CD14, and
CD11a is up-regulated. Finally, resveratrol promotes dose-
dependently the expression of osteoblast markers like osteo-
calcin and osteopontin in human bone marrow mesenchymal
stem cells (hMSC-TERT) and stimulates their response to
1,25(OH)2 vitamin D3 [1,25(OH)2D3]. Moreover, resveratrol
up-regulates dose-dependently the expression of 1,25(OH)2D3
nuclear receptor. Taken together, these results suggest that
resveratrol or its derivatives deserve attention as potential
drugs for treating multiple myeloma. (Cancer Res 2005; 65(21):
9943-52)
Introduction
Multiple myeloma is an incurable disease characterized
primarily by the accumulation of clonal plasma cells in the bone
marrow ( for a review, see ref. 1). This accumulation alters
dramatically the activity of neighboring cells, which leads to a
fatal disorder associated with severe bone complications. Current
treatments, such as chemotherapy, radiotherapy, bisphosphonates,
and autologous peripheral stem cell transplantation, allow a
median survival of f5 to 7 years. Patients who respond to
treatments eventually relapse and become resistant. There is thus
an urgent need for more efficient treatment and for an
identification of the pathways leading to the major pathologic
events associated to myeloma.
Interactions of myeloma cells with the bone marrow micro-
environment seem to be a major driving force for disease
development (2). Through interactions with bone marrow stromal
cells, myeloma cells stimulate production of survival/proliferation
factors as well as osteoclast-activating cytokines, such as
interleukin (IL)-6, IL-1, macrophage inflammatory protein-1a,
tumor necrosis factor-a, macrophage colony-stimulating factor
(M-CSF; refs. 2, 3), and the tumor necrosis factor family member
receptor activator of nuclear factor-nB (NF-nB) ligand (RANKL;
ref. 4). In contrast, osteoprotegerin, the decoy receptor of RANKL,
is down-regulated (4). M-CSF, RANKL, and osteoprotegerin play
key functions in osteoclastogenesis: M-CSF acts as a growth and
survival factor for the common monocytic precursor shared
between macrophages and osteoclasts (5), and RANKL stimulates
osteoclast differentiation (6), activation (7), and migration (8). In
multiple myeloma, the high RANKL/osteoprotegerin ratio leads to
an increase of the number of osteoclasts and enhanced bone
resorption (9). In turn, increased osteoclastic activity promotes
myeloma cell proliferation and survival (10, 11). Enhancement of
bone resorption is normally associated with increased bone
formation, allowing rebuilding the bone that was removed, but a
striking feature of myeloma is that bone lesions are not repaired,
because osteoblast function is deficient (12). Recent studies
suggest that this deficiency is due to the production of DKK1 by
myeloma cells, a soluble factor that can antagonize the Wnt
signaling pathway during osteoblast differentiation (13).
Resveratrol (trans-3,4V,5-trihydroxystilbene) is a natural com-
pound present in various plant species and relatively abundant in
wine (up to 25 Amol/L; ref. 14). Resveratrol is raising a lot of
interest because of a series of observations suggesting that it has
cancer chemopreventive properties ( for a review, see ref. 15).
Resveratrol was found to inhibit tumorigenesis in rodent cancer
models (16); to inhibit proliferation and induce apoptosis in
several human cancer cells, including B-cell malignancies (17);
and to affect a series of critical events associated with tumor
initiation and progression, including up-regulation of p53 and p21
levels, induction of nitric oxide, inhibition of cyclooxygenase,
protection against reactive oxygen intermediates, down-regulation
of survival factors, and down-regulation of proteinases (18, 19).
Effects of resveratrol have been documented in a wide variety of
cell types, including macrophages, polymorphonuclear cells,
platelets, osteoblasts, neurons, and adrenal cells, and it was
suggested that resveratrol has therapeutic potential for allergy
and cardiovascular and neurologic disorders (19, 20). In the
present study, we have investigated the effect of resveratrol on
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three major events associated with multiple myeloma and found
that resveratrol inhibits myeloma cell growth, prevents osteo-
clastogenesis and bone resorption, and promotes osteoblast
differentiation.
Materials and Methods
Reagents and cell lines. Recombinant human M-CSF (rhM-CSF) and
soluble human recombinant RANKL (rhRANKL) were obtained from
Peprotech (London, United Kingdom), resveratrol from Sigma (Brøndby,
Denmark), and 1,25(OH)2 vitamin D3 [1,25(OH)2D3] from Leo Pharma
(Ballerup, Denmark). Human myeloma cell lines RPMI 8226 and OPM-2
were obtained from the cell line bank DSMZ (Braunschweig, Germany) and
grown in RPMI 1640 (Life Technologies/Invitrogen, Tastrup, Denmark)
supplemented with 10% FCS. hMSC-TERT is a well-characterized cell line
established from normal human bone marrow mesenchymal stem cells
(hMSC) that stably expresses human telomerase reverse transcriptase gene
(TERT) and thus its name hMSC-TERT (21). All cells were cultured at 37jC
in a humidified atmosphere with 5% CO2.
Cell growth assay. Myeloma cell lines were cultured in microtiter plates
in serum-free medium for 3 days at 37jC. The number of cells per well was
assessed with 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxanilide inner salt (XTT) kit (Boehringer Mannheim, Roche Molecular
Biochemicals, Hvidovre, Denmark) at different time points according to the
manufacturer’s instruction. XTT was proven comparable with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide but is water soluble.
In vitro osteoclast differentiation and resorption assays. Human
osteoclast precursors were prepared from the blood of healthy donors
provided anonymously by the blood bank of Vejle Hospital. Peripheral blood
mononuclear cells (PBMC) were first separated by centrifugation on Ficoll-
Paque PLUS (Amersham Biosciences, Hillerød, Denmark); then, monocytes
were isolated by magnetic cell sorting according to the manufacturer’s
instruction. Briefly, PBMCs resuspended in 2% FCS in PBS were incubated
first with biotinylated anti-human CD14 goat antibody (R&D Systems,
Abingdon, United Kingdom) for 15 minutes at 4jC and then with Magcellect
streptavidin ferrofluid (R&D Systems) for 15minutes at 4jC. After incubation,
tagged cells were retained by a magnetic device, whereas negative cells were
discarded by extensive washes in 2% FCS in PBS. Finally, sorted cells were
cultured in a-MEM (Life Technologies/Invitrogen) supplemented with 10%
FCS ( full medium) and 30 ng/mL rhM-CSF for 3 days at 37jC. For osteoclast
differentiation, adherent monocytes were trypsinized and reseeded at
defined cell densities in cell culture plates in full medium supplemented
with 30 ng/mL rhM-CSF. The day after, supernatants were replaced by
osteoclast differentiation medium containing both 30 ng/mL rhM-CSF and
30 ng/mL rhRANKL with different concentrations of resveratrol. Cells were
cultured for 6 to 7 days with replacement of medium every second day.
To monitor osteoclast differentiation, both tartrate-resistant acid
phosphatase (TRACP) activity and the number of TRACP multinucleated
cells were examined. Conditioned media were collected at different times,
and TRACP activity was colorimetrically measured by adding p-nitrophenyl
phosphate (Sigma) in the presence of 25 mmol/L sodium tartrate (pH 5.5;
absorbance, 405-645 nm). At the end of the experiment, cells were fixed with
4% formaldehyde and stained for TRACP using the Leukocyte Acid
Phosphatase kit (Sigma). The number of TRACP-positive multinucleated
cells was counted using Metavue software (Universal Imaging Corp., Brock
& Michelsen, Birkerød, Denmark) after taking randomly pictures in different
areas of each well.
For resorption assay, cells were handled like described above but seeded
on dentine discs (Immunodiagnostic System Ltd., Boldon, United Kingdom).
Cells were cultured at 37jC up to 12 days and medium was replaced every
second day. At the end, cells were scraped off in water containing 1% Triton
X-100 and resorption pits were detected using peroxidase-conjugated wheat
germ agglutinin (WGA)-lectin according to Selander et al. (22). 3,3V-
Diaminobenzidine-based staining of peroxidase activity (Sigma) was
enhanced with ammonium nickel sulfate (Sigma), which gives a black
precipitate. The resorbed areas on the dentine discs were measured with
Metavue software, and results were presented as the total resorbed area in
percentage of the whole disc surface.
Osteoblast differentiation. hMSC-TERTcells were grown in phenol red–
free MEM supplemented with 10% FCS. At 60% to 70% cell confluence, cells
were incubated with fresh complete medium containing different concen-
trations of resveratrol in the absence or presence of 109 mol/L 1,25(OH)2D3.
Real-time PCR analysis of osteoclast cultures. Cultures of monocytes
taken at different time points were lysed and homogenized by centrifugation
through QIAShredder columns (Qiagen, Hilden, Germany). Total RNA was
purified from the homogenate using the RNeasy Mini kit (Qiagen) and then
reverse transcribed into single-stranded cDNA using the Iscript cDNA
synthesis kit (Bio-Rad Laboratories, Herts, United Kingdom) according to the
manufacturer’s instructions.
Relative gene expression was analyzed by Taqman-based quantitative
real time-PCR as described previously (23) with a ABI PRISM 7900HT
sequence detection system and software (PE Applied Biosystems, Inc.,
Naerum, Denmark). Primers and probes for the Taqman system were
obtained as an Assay-on-Demand (PE Applied Biosystems) or designed to
meet the specific criteria by using Primer Express 2.0 software (PE Applied
Biosystems) and subsequently synthesized by MWG (Risskov, Denmark).
The Assays-on-Demand, which contained MGP probes labeled with the
fluorescence reporter FAM, were used for the analysis of cathepsin K
(Hs00355885_m1), h-actin (4333762F), RANK (Hs00187189_m1), c-fms
(Hs00234617_m1), CD14 (hs00169122_q1), and CD11a (Hs00158218_m1).
NFATc1 primers and probe were designed according to the NFATc1
Genbank accession no. U08015: NFATc1-fp TGGAGAGTCCTCGCATCGA,
NFATc1-rp: CATCGTGGAAAAACTGGTTATTGT and NFATc1-p: ATAACC-
TCGTGCTTGGGCCTGTACCAC.
After PCR reactions in standard conditions, Ct values were converted into
relative gene expression according to an arbitrary standard curve and
normalized to the relative gene expression of an endogenous control using
the relative standard curve method according to the PE Applied Biosystems
instructions. When testing different endogenous control genes using the
primers/probe sets described previously by Beillard et al. (24), h-actin was
found to be appropriate, showing no difference between different culture
conditions.
Real-time PCR analysis of osteoblastic markers. Total RNA was
isolated from cultured hMSC-TERT cells using single-step method with
TRIzol according to themanufacturer’s instructions (Invitrogen A/S, Tastrup,
Denmark). The integrity and purity of total RNA was verified by
spectrophotometry and gel electrophoresis on 0.8% SeaKem agarose (BMA,
Hellerup, Denmark). Total RNA (5 Ag) was then reverse transcribed into DNA
using RevertAid H Minus first-strand cDNA synthesis kit (Fermentas,
Copenhagen, Denmark) according to the manufacturer’s instructions.
Quantitative PCR was done with an iCycler IQ detection system (Bio-Rad
Laboratories) by using SYBR Green I as a double-strand DNA-specific binding
dye. Thermocycling was done in a final volume of 20 AL containing 3 AL cDNA
sample (diluted 1:30), 20 pmol of each primer, 2 mmol/L MgCl2, 0.2 mmol/L
deoxynucleotide triphosphate mixture, 1 Taq reaction buffer, 0.5 units
HotStart Taq DNA polymerase (Qiagen), 0.5 AL of 1:3,000 dilution of SYBR
Green I (Roche Molecular Biochemicals), and 10 nmol/L fluorescein
calibration dye (Bio-Rad Laboratories). The gene expression analysis of the
target gene and the endogenous control h-actin was done in separate tubes
using the primers used previously by Abdallah et al. (25). After initial
denaturation at 95jC for 10 minutes, 40 cycles of denaturation at 95jC for
30 seconds, annealing at 60jC for 30 seconds, and extension at 72jC for
1 minute were carried out. Each reaction was run in triplicates and the
fluorescence datawere specified for collection at the end of the extension step
in every cycle.
To ensure specific amplification, a melting curve was made for each PCR
reaction by increasing the temperature from 60jC to 95jC with
temperature increment rate of 0.5jC/10 s.
Fold induction and expression levels for each target gene and
endogenous control were calculated using the comparative Ct method
[(1 / (2DCt)] formula [Perkin-Elmer (Hvidore, Denmark) User Bulletin No. 2].
Data were analyzed using the optical system software version 3.1 (Bio-Rad
Laboratories).
Cancer Research
Cancer Res 2005; 65: (21). November 1, 2005 9944 www.aacrjournals.org
Flow cytometry. Flow cytometry analyses were done on a FACSCalibur
(BD Biosciences, Brødby, Denmark) using CellQuest Pro software. For
detection of cell surface RANK, monocytes were washed in PBS and
detached with 5 mmol/L EDTA in bovine serum albumin (BSA)/PBS.
Resuspended cells were incubated with a biotinylated goat anti-RANK
polyclonal antibody (R&D Systems) or control antibody (biotinylated
normal goat immunoglobulin; R&D Systems) in BSA/PBS for 30 minutes
at 4jC, washed several times, and then incubated with FITC-conjugated
streptavidin (DAKO, Glostrup, Denmark) in BSA/PBS for 30 minutes at 4jC.
After several washes, cells were fixed in 1% paraformaldehyde.
For apoptosis analysis, myeloma cells were washed twice in PBS and then
subjected either to FITC-conjugated Annexin V staining according to the
manufacturer’s instruction (BD Biosciences) or propidium iodide (PI)
staining for measuring cell DNA content. For the latter method, cells were
fixed in 70% ethanol at 20jC overnight and then incubated with PBS
containing 100 Ag/mL RNase and 40 Ag/mL PI for 30 minutes at room
temperature. The data were measured on a linear scale and apoptotic cells
were evaluated as a sub-G1 hypodiploid cell population.
In situ detection of nuclear factor-KB nuclear translocation.
Monocytes were incubated with 100 Amol/L resveratrol for 1 hour or
3 days in full medium containing 30 ng/mL rhM-CSF and then exposed to 100
ng/mL rhRANKL for 30 minutes at 37C. Cells were fixed in 4%
paraformaldehyde for 10 minutes at room temperature followed by a second
fixation/permeabilization with cold methanol for 15 minutes at20jC. Cells
were incubated with a mouse monoclonal anti-p65 antibody (Santa Cruz
Biotechnology, AH Diagnostics, Aarhus, Denmark) in BSA/PBS overnight at
4jC, washed several times in PBS, and then incubatedwith a secondary Alexa
Fluor-568 goat anti-mouse IgG antibody (Molecular Probes, Invitrogen,
Taastrup, Denmark) in BSA/PBS for 1 hour at room temperature. After several
washes, the nucleus of cells was counterstained with Hoechst 33258 (Sigma).
Cells showing a bright staining for p65 in the nucleus were scored, and the
results were presented as the number of cells with NF-nB nuclear
translocation in percentage of the total number of cells scrutinized.
Statistics. Statistical differences between groups were analyzed using
one-way ANOVA followed by Dunnett’s or Bonferroni’s post-test. Data
presented are from a single experiment and representative for at least three
independent experiments.
Results
Resveratrol inhibits growth of myeloma cells and induces
apoptosis. Two myeloma cell lines OPM-2 and RPMI 8226 were
maintained in culture for 2 or 3 days in the presence of increasing
concentrations of resveratrol. In absence of resveratrol, RPMI 8226
and OPM-2 cells showed a high proliferation rate reflected by a
3- to 4-fold increase of the total cell metabolic activity after 2 to
3 days of culture (Fig. 1A and B). Addition of resveratrol decreased
dose-dependently the number of living myeloma cells the second
day and onwards. The effect was significant above 25 Amol/L
resveratrol. After a 3-day culture in the presence of 100 Amol/L
resveratrol, the net metabolic activity was equal to or lower than at
day 0, showing that high resveratrol concentrations can prevent
completely myeloma cell growth.
To understand further how resveratrol mediated myeloma cell
growth inhibition, we examined the incidence of apoptosis in our
cell cultures. Treating OPM-2 cells for 2 days with 25 or 100 Amol/L
resveratrol strongly increased the population of Annexin V–
positive (Fig. 1C) and sub-G1 hypodiploid cells (Fig. 1D), two
characteristics of cells undergoing apoptosis.
Taken together, our results show that resveratrol reduces
significantly myeloma cell growth by a mechanism involving cell
apoptosis.
Resveratrol prevents receptor activator of nuclear factor-KB
ligand–induced osteoclast differentiation. Because myeloma
cells stimulate the recruitment of osteoclasts, we investigated
whether resveratrol might affect osteoclast differentiation. There-
fore, human PBMC-isolated monocytes were cultured with 30 ng/mL
M-CSF and 30 ng/mL RANKL for 3 and 7 days. When compared
with cultures with M-CSF alone, the presence of RANKL induced
numerous TRACP multinucleated cells (Fig. 2A), increased strongly
TRACP activity in the medium (Fig. 2B), and stimulated the
expression of cathepsin K mRNA (Fig. 2C), all hallmarks of
Figure 1. Resveratrol (RSV ) inhibits
growth and induces apoptosis of myeloma
cells. RPMI 8226 and OPM-2 cell lines
were cultured for 2 or 3 days in the
presence of resveratrol at the indicated
concentrations. The relative number of
RPMI 8226 (A) and OPM-2 (B ) cells was
assessed with the XTT assay. 100%
represents the relative cell number at the
start of cell cultures. Columns, mean of five
cultures; bars, SD. *, P < 0.01 versus
untreated cells. OPM-2 cells were
incubated for 2 days in the absence or
presence of different concentrations of
resveratrol and examined for apoptosis by
measuring by flow cytometry the
percentage of cells stained with
FITC-conjugated Annexin V (C) and the
percentage of cells showing a lower DNA
content after PI staining (D ).
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osteoclast differentiation. Addition of resveratrol to the cultures
inhibited the RANKL-induced formation of multinucleated cells in
a dose-dependent manner (significant at z12.5 Amol/L) with a
complete abrogation at 100 Amol/L resveratrol (Fig. 2A as well as
Fig. 3B , 6-day treatment). This resveratrol effect was concomitant
with a strong decrease of TRACP activity in the culture medium
(Fig. 2B) and of cathepsin K expression (Fig. 2C). These decreases
in TRAP activity and cathepsin K expression were both dependent
on the same range of resveratrol concentrations with full inhibition
of RANKL-induced up-regulation at 100 Amol/L.
To examine whether resveratrol affects the growth/survival of
monocytes during their differentiation into osteoclasts, we
monitored the number of cells with a XTT assay. After 3 days of
culture in the presence of M-CSF and RANKL, no significant
difference was found between cell cultures without or with
resveratrol at concentrations ranging from 12.5 to 100 Amol/L
(data not shown). At day 7, resveratrol concentrations of 50 and
100 Amol/L brought the cell numbers down to 68.10 F 5.13% and
68.10 F 6.19%, respectively (mean F SD; control, 100 F 3.58%;
n = 4). Cells incubated for 7 days with M-CSF plus RANKL and 100
Amol/L resveratrol exhibited a striking elongated morphology,
which is not all typical of cells undergoing apoptosis. Furthermore,
DNA staining with Hoechst dye did not reveal any increase of DNA
condensation/fragmentation in these cells compared with cells
cultured in the absence of resveratrol (data not shown).
To determine which stage of osteoclast differentiation is impaired
by resveratrol, we followed RANKL-induced TRACP activity and
number of TRACP multinucleated cells in cultures treated with
resveratrol either from days 0 to 3 or from days 3 to 6, which is the
period when cells start fusing. We found that resveratrol was
inhibitory both during the RANKL-mediated early activation (Fig. 3,
days 0-3) and during the cell fusion period (days 3-6) but to a lesser
extent than in the full-course inhibition (days 0-6). Although an
effect of resveratrol on osteoclast differentiation was visible in all
treatment periods, the elongated cell morphology observed at
100 Amol/L resveratrol was lost 3 days after resveratrol withdrawal
(Fig. 3C , resveratrol during days 0-3 versus days 3-6 or days 0-6),
showing a reversible effect on cell morphology.
Finally, the effect of resveratrol on osteoclast resorption activity
was investigated by culturing monocytes on dentine discs in the
presence of M-CSF and RANKL (Fig. 4). Resveratrol inhibited dose-
dependently RANKL-induced pit formation. Concentrations of
z25 Amol/L were close to fully inhibiting (Fig. 4B).
We thus conclude that resveratrol is a strong inhibitor of
osteoclast differentiation and resorption.
Resveratrol prevents receptor activator of nuclear factor-KB
ligand signaling and favors expression of myeloid markers.
To determine whether resveratrol acts on RANKL signaling, we
examined the gene expression of NFATc1, a key transcription factor
regulated by RANKL and reported to be essential for the osteoclast
differentiation program (26, 27). As expected, stimulation of
monocytes with RANKL significantly increased NFATc1 mRNA
level in a time-dependent way (Fig. 5A). This up-regulation was
inhibited by resveratrol dose-dependently, at the same concen-
trations as those inhibiting osteoclast differentiation, and 100
Amol/L inhibited completely both events.
Figure 2. Resveratrol inhibits RANKL-induced osteoclast differentiation.
PBMC-isolated monocytes were cultured with 30 ng/mL rhM-CSF with or without
30 ng/mL rhRANKL for 7 days. In conditions with RANKL, cells were treated
for the entire culture period with 0, 1, 25, 50, or 100 Amol/L resveratrol.
A, morphology of the cells at the end of the cell cultures after TRACP staining:
culture with M-CSF alone or M-CSF + RANKL in the presence of 25 or 100 Amol/L
resveratrol. B, relative level of TRACP activity detected in conditioned media
after culture for 3 and 7 days. Columns, mean of four cultures; bars, SD.
*, P < 0.01, statistically significant resveratrol effects versus cultures with M-CSF
+ RANKL. C, relative gene expression of cathepsin K measured by quantitative
real-time PCR in cells cultured for 3 or 7 days with M-CSF or M-CSF + RANKL in
the absence or presence of 100 Amol/L resveratrol (left ) or in 7-day culture
treated with M-CSF or M-CSF + RANKL in the presence of increasing
concentrations of resveratrol (right ). The levels of cathepsin K mRNA were
normalized to h-actin mRNA and are represented as induction fold compared
with cells cultured with M-CSF alone for 3 days (left ) or 7 days (right ).
Columns, mean of four cultures; bars, SD. *, P < 0.001.
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Because RANK is obligatory for transducing RANKL signaling
into the cells, we examined the effect of resveratrol on its expres-
sion. Addition of 100 Amol/L resveratrol to cells in their differen-
tiating medium resulted in a drop of RANK mRNA (Fig. 5B). After
3 days, the decrease reached already 50%, and RANK protein
expression on the cell surface was also much lower (Fig. 5B).
Because RANKL-induced osteoclastogenesis involves the activa-
tion of NF-nB, we examinedwhether resveratrol affects this signaling
pathway in our cultures. The level of NF-nB activation can be
efficiently assessed in osteoclasts by visualizing its translocation
from the cytosol to the nucleus after being released from InB on
RANKL stimulation (28). NF-nB nuclear translocation is transient
and is detected within 30 minutes after RANKL exposure, whereas
1 hour later the factor becomes again predominantly localized in the
cytoplasm. Similarly, stimulation of our monocytes with RANKL for
30 minutes strongly induced NF-nB nuclear translocation (21.7 F
2.5%) compared with cultures without RANKL (0.5 F 0.2%; Fig. 5C).
Interestingly, pretreating the cells with 100 Amol/L resveratrol for
3 days reduced the stimulation by RANKL by >50% (9.7 F 1.9%). On
the other hand, pretreating the cells for only 1 hour with 100 Amol/L
resveratrol had no effect on the level of RANKL-induced NF-nB
translocation (22.8 F 5.2%). It should be noticed that resveratrol
(3 days or 1 hour) did not affect the NF-nB signal in the absence of
RANKL (data not shown).
Figure 3. Resveratrol acts on different stages of osteoclast differentiation.
PBMC-isolated monocytes were cultured with 30 ng/mL rhM-CSF alone or
together with 30 ng/mL rhRANKL for 6 days. Cells were treated with different
concentrations of resveratrol either from days 0 to 3 or from days 3 to 6 or during
the full-length of cell cultures. A, relative level of TRACP activity in media
collected at day 6. B, relative number of TRACP-stained multinucleated cells
(MNCs ; number of nuclei per cell is >2). Columns, mean of four independent
cultures; bars, SD (A and B). *, P < 0.01, statistically significant resveratrol
effects versus cultures with M-CSF + RANKL. C, illustrations of the morphology
of the cells after 6 days of culture with M-CSF + RANKL supplemented with
100 Amol/L resveratrol either from days 0 to 3 or from days 3 to 6 or during
the entire cell culture.
Figure 4. Inhibition of osteoclast differentiation by resveratrol prevents the
formation of pits in dentine discs. PBMC-isolated monocytes were cultured
with 30 ng/mL rhM-CSF alone or together with 30 ng/mL rhRANKL for 12 days
on dentine discs in the absence or presence of increasing concentrations of
resveratrol. Thereafter, cells were wiped off and excavated pits were detected
with peroxidase-conjugated WGA-lectin and stained with appropriate peroxidase
substrate. A, percentage of total resorbed area. Columns, mean of four
cultures; bars, SD. *, P < 0.01, statistically significant resveratrol effects
versus cultures with M-CSF + RANKL. B, illustrations of resorption pits in dentine
discs on which cells were differentiated into osteoclasts in the presence of
M-CSF + RANKL. In cultures supplemented with 50 Amol/L resveratrol, no
pits could be found.
Resveratrol and Multiple Myeloma
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Finally, to characterize further the phenotype of the monocytic
cells treated with resveratrol in osteoclast differentiating medium,
we examined the expression pattern of several genes related to
monocyte lineage (Fig. 5D). In contrast with its effect on RANK and
NFATc1, resveratrol up-regulated strongly the mRNA level of c-fms
(M-CSF receptor) and CD14 [lipopolysaccharide (LPS)/LPS-binding
protein receptor], two genes that were not regulated during
RANKL-induced osteoclast differentiation. In addition, we found
that resveratrol also increased the level of CD11a mRNA (aL
subunit of LFA1 integrin) that was significantly down-regulated
during RANKL-induced osteoclast differentiation.
Taken together, our results show that resveratrol inhibits
osteoclast differentiation at least in part by impairing RANKL
signaling in osteoclast precursors and that resveratrol-treated cells
exhibit a more pronounced expression of monocyte lineage markers.
Resveratrol stimulates vitamin D receptor expression in
bone marrow osteoblast precursors and synergizes with
1,25(OH)2 vitamin D3 to induce expression of osteocalcin
and osteopontin genes. Myeloma cells inhibit osteoblast differ-
entiation (12, 13). We thus investigated whether resveratrol could
favor bone formation by stimulating osteoblast differentiation.
Therefore, we analyzed the effect of resveratrol on a human bone
marrow mesenchymal stem cell line, hMSC-TERT. These cells have
kept the potential to differentiate into osteoblasts in vivo after
s.c. implantation in immunodeficient-mice (21) or in vitro when
treated for 3 days in cultures with the osteogenic hormone,
1,25(OH)2D3 (25). We first cultured hMSC-TERT cells for 3 days
in the presence of increasing concentrations of resveratrol and
analyzed by quantitative PCR the relative gene expression of
two late markers of osteoblast differentiation, osteocalcin and
Figure 5. Resveratrol impairs RANK and NFATc1 expression as well as NF-nB translocation while up-regulating c-fms, CD14, and CD11a expression. A, relative
gene expression of NFATc1 measured by quantitative real-time PCR in monocytes cultured for 3 or 7 days with M-CSF or M-CSF + RANKL in the absence or
presence of 100 Amol/L resveratrol (left ) or in 7-day cultures treated with M-CSF or M-CSF + RANKL in the presence of increasing concentrations of resveratrol
(right ). Levels of mRNA expression were normalized to h-actin and are represented as induction fold compared with cells cultured with M-CSF alone for 3 days (left)
and 7 days (right ). Columns, mean of four cultures; bars, SD. *, P < 0.001. B, left, relative gene expression of RANK in monocytes cultured for 3 or 7 days with M-CSF
or M-CSF + RANKL in the absence or presence of 100 Amol/L resveratrol. Levels of mRNA expression were normalized to h-actin and are represented as induction
fold compared with cells cultured with M-CSF alone at day 3. Columns, mean of four cultures; bars, SD. *, P < 0.001. Right, level of RANK expression on the cell
surface analyzed by flow cytometry. Monocytes were cultured for 3 days with M-CSF + RANKL in the absence or presence of 100 Amol/L resveratrol. Thin line,
isotypic control; filled histogram, untreated cells; thick line, cells treated with resveratrol. C, detection by immunofluorescence of RANKL-induced NF-nB nuclear
translocation in cultures of monocytes treated with 100 Amol/L resveratrol for 1 hour or 3 days. In absence of RANKL, most of the cells showed a cytoplasmic localization
of NF-nB (W/O ), whereas after 30 minutes RANKL exposure f20% cells displayed a strong nuclear staining (With RANKL). Asterisks, cell nuclei. Graphs show
the number of cells with NF-nB nuclear translocation in percentage of the total number of scrutinized cells (counting >400 cells per culture). Columns, mean of
four cultures; bars, SD. *, P < 0.01. D, relative gene expression of c-fms, CD14, and CD11a in cells cultured for 3 or 7 days with M-CSF or M-CSF + RANKL in
the absence or presence of 100 Amol/L resveratrol. Levels of mRNA expression were normalized to h-actin and are represented as induction fold compared with
cells cultured with M-CSF alone at day 3. Columns, mean of four cultures; bars, SD. *, P < 0.001.
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osteopontin. Resveratrol alone stimulated the mRNA expression of
osteocalcin and osteopontin in a dose-dependent manner with
a statistically significant effect above 25 Amol/L (Fig. 6A, inset ,
and B). At 100 Amol/L, resveratrol stimulated osteocalcin and
osteopontin mRNA expression 3- and 18-fold, respectively. If
osteoblast differentiation was induced with a suboptimal concen-
tration of 1,25(OH)2D3 (10
9 mol/L), the effect of resveratrol was
much greater and still dose dependent (Fig. 6A and B): whereas
109 mol/L 1,25(OH)2D3 alone induced a 36- and 3-fold increase of
osteocalcin and osteopontin mRNA expression, respectively,
costimulation with 100 Amol/L resveratrol raised the level of
osteocalcin and osteopontin mRNA up to 207- and 45-fold,
respectively. Because 1,25(OH)2D3 is known to activate directly
transcriptional promoters of osteocalcin and osteopontin genes
(29), we examined the relative gene expression of the nuclear
receptor of 1,25(OH)2D3 [vitamin D receptor (VDR); Fig. 6C].
Interestingly, we found that VDR mRNA expression was also up-
regulated by resveratrol in a dose-dependent manner and that
resveratrol displayed a synergistic effect with 1,25(OH)2D3 at z25
Amol/L. In summary, our results show that resveratrol stimulates
the expression of two osteoblastic markers, osteocalcin and
osteopontin, in bone marrow mesenchymal stem cells and has a
synergistic effect with 1,25(OH)2D3 on their expression most likely
because resveratrol also up-regulates VDR gene expression.
Discussion
In multiple myeloma, the accumulation of malignant plasma cells
in the bone marrow cavity causes profound changes in their
microenvironment. Serious consequences are increased osteoclast
formation and bone resorption and absence of osteoblast recruit-
ment and bone formation (30). Furthermore, bone resorption
promotes myeloma cell growth (10, 11). The overall consequence
is a vicious cycle with accelerated bone loss and progression of
myeloma. The ideal treatment of multiple myeloma patients should
thus aim at preventing myeloma cell growth, inhibiting bone
resorption, and promoting bone formation. Our study shows that
resveratrol exhibits precisely this set of properties: it prevents
growth of myeloma cells, inhibits osteoclast differentiation and bone
resorption, and favors osteoblast differentiation.
Our demonstration that resveratrol prevents osteoclast differ-
entiation is based on several observations. In cultures of PBMC-
isolated monocytes treated with M-CSF and RANKL, the same
concentrations of resveratrol inhibit the formation of TRACP
multinucleated cells; pit formation on dentine discs; release of
TRACP, a well-established osteoclast marker, in the conditioned
medium; and up-regulation of cathepsin K, the key protease for
osteoclastic bone degradation (31). Furthermore, we provide
insight in the mode of action of resveratrol on osteoclast
differentiation and show that resveratrol interferes with RANKL
signaling. This cytokine is indispensable for triggering the full
osteoclast differentiation program and is the most important
cytokine for osteoclast recruitment and activation in multiple
myeloma (30). First, we show that resveratrol down-regulates
mRNA and cell surface levels of RANK, the RANKL receptor that is
expressed on the osteoclast precursors. Secondly, we show that
resveratrol reduces the level of the RANKL-triggered NF-nB
activation, a transcription factor that is essential for osteoclast
differentiation (32). Interestingly, resveratrol was already reported
to act on NF-nB activation in several cell types (19), but its effect in
our cultures occurred only after several days, suggesting that
resveratrol does not target directly this signaling cascade. Finally,
we show that resveratrol prevents the induction of NFATc1 by
RANKL, a downstream transcription factor reported recently to be
indispensable for switching monocytes into osteoclasts (26, 27).
It is noteworthy that the dose dependency of the inhibitory acti-
vity of resveratrol against NFATc1 and osteoclast differentiation is
Figure 6. Resveratrol induces gene expression of osteocalcin (OC ) and
osteopontin (OPN ) in TERT cells, synergizes their response to 1,25(OH)2D3,
and up-regulates expression of 1,25(OH)2D3 nuclear receptor. hMSC-TERT
cells were cultured for 3 days with or without 109 mol/L 1,25(OH)2D3 in the
presence of the indicated resveratrol concentrations. RNA was purified and the
expression of osteocalcin (A ), osteopontin (B ), and VDR (C ) was evaluated by
quantitative real-time PCR. Levels of mRNA expression were normalized to
h-actin mRNA and are represented as induction-fold compared with the condition
without 1,25(OH)2D3 and without resveratrol. Columns, mean of three
independent experiments; bars, SD. Note that the inset in (A) shows the values
of the conditions without 1,25(OH)2D3 with another Y-scale. *, P < 0.01,
statistically significant resveratrol effects versus cultures without resveratrol.
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similar, suggesting a close relation with its effects on osteoclast
differentiation. Thus far, it is not clear to what extent the effects of
resveratrol on RANK, NF-nB, and NFATc1 are interrelated. For
instance, it has been reported recently that inhibition of osteoclast
differentiation obtained by using a NF-nB inhibitor correlate with a
down-regulation of NFATc1, suggesting that NF-nB regulates
NFATc1 (33). One may thus speculate that a low activation
of NF-nB together with low RANK expression contributes to
impaired NFATc1 stimulation. Additional targets of resveratrol can
of course not be excluded. In addition to its action on RANKL
signaling, resveratrol may also affect cell changes occurring during
the terminal differentiation of osteoclasts. Indeed, we found that
the formation of osteoclasts was also inhibited when resveratrol
was added 3 days after RANKL, at a time point where NFATc1 is
already activated (Fig. 5A). Because cell spreading is a required step
for monocytes to form multinucleated cells (34), one may speculate
that the dramatic morphologic change induced by resveratrol
impairs cell fusion process. Taken together, our findings show that
resveratrol can inhibit osteoclastogenesis at several critical steps,
including RANKL signaling. Because RANKL is a key factor in
enhanced osteoclastogenesis in multiple myeloma, we propose that
resveratrol could be an efficient osteoclast inhibitor in multiple
myeloma.
The effects of resveratrol on osteoclastogenesis cannot be
merely ascribed to a nonspecific toxic effect of resveratrol. After
3-day resveratrol treatment, when the effects exerted by
resveratrol on gene expressions and NF-nB signaling were already
significant, there was no reduction in the number of viable cells.
Even if a 7-day treatment resulted in a 30% reduction in cell
number, there was no indication of resveratrol-induced apoptosis.
Cell densities remained high (Figs. 2A and 3C), and the most
striking feature was the elongation of the cells. Furthermore, in
the same cell cultures where resveratrol induced a decrease in
RANK, NFATc1, cathepsin K, and TRACP, there was a concom-
itant increase in c-fms, CD14, and CD11a expression. The up-
regulation of these genes by resveratrol suggests a relationship
of these cells with the monocyte/macrophage lineage. Finally, our
observations suggest that the effect of resveratrol may be
reversible, because, after resveratrol withdrawal, elongated
morphology started being lost and similarity to cells stimulated
with M-CSF alone increased (Fig. 3C).
A peculiarity of multiple myeloma bone disease is that increased
bone resorption is not compensated by bone formation (12).
Formation of new bone requires mature osteoblasts producing
extracellular matrix. Osteoblasts differentiate from bone marrow
stromal cells, so-called mesenchymal stem cells in response to local
factors as well as to systemic hormones like parathyroid hormone
or 1,25(OH)2D3 (35). In multiple myeloma, osteoblast numbers are
reduced (12). The mechanism is not well understood, but
myeloma-stromal cell interactions and the soluble Wnt signaling
antagonist DKK1 have been implicated in the inhibition of
osteoblast differentiation (13, 36). Up-regulation of osteocalcin
and osteopontin are well-established indicators of late-stage
osteoblastic differentiation (37). Osteocalcin levels in blood allow
monitoring bone formation and are decreased in multiple myeloma
patients (38). It is thus of interest that our study shows that
resveratrol can stimulate osteocalcin and osteopontin expression
dose-dependently in the multipotent hMSC-TERT cells, a cell line
able to commit into osteoblasts (21, 25). Similar effects were
observed while using normal human bone marrow stromal cells
(data not shown). Moreover, resveratrol at concentrations between
25 and 100 Amol/L synergizes with 1,25(OH)2D3 to induce
osteocalcin and, to a lesser extent, osteopontin expression. These
effects of resveratrol suggest that resveratrol can commit early
osteoprogenitor cells in bone marrow into the osteoblastic lineage.
In agreement with our results, Mizutani et al. have reported that
alkaline phosphatase, another marker of osteoblast differentiation,
is also increased by resveratrol in mouse osteoblastic MC3T3 cells,
which are cells at a later stage of osteoblast maturation (20). Taken
together, these data support a stimulatory effect of resveratrol on
osteoblast commitment and differentiation. With respect to the
mode of action of resveratrol on osteoblast differentiation, we
found that resveratrol regulates VDR, the nuclear receptor of
1,25(OH)2D3, dose-dependently. Because 1,25(OH)2D3 directly
targets the osteocalcin and osteopontin gene promoters via the
VDR (29), one could speculate that resveratrol-induced up-
regulation of VDR may enhance greatly the responsiveness of
bone marrow stromal cells to 1,25(OH)2D3 and thereby stimulate
osteoblast differentiation.
Finally, we found that resveratrol reduces cell growth of two
different myeloma cell lines in a dose-dependent manner by a
mechanism involving cell apoptosis. Similarly to our observations,
Jazirehi et al. (17) have shown that resveratrol induces cell cycle
arrest and triggers apoptosis in non-Hodgkin’s lymphoma, another
B-cell–derived tumor. The authors also found that the combination
of resveratrol and paclitaxel, a chemotherapeutic agent, enhanced
cell death in non-Hodgkin’s lymphoma and myeloma cells. Another
recent study has shown that resveratrol can sensitize the myeloma
cell line IM-9 to radiation when used at high concentrations (39).
In addition, it is worthwhile noticing that concentrations of
resveratrol reported to induce apoptosis in different blood cancer
cell lines do not affect the survival of normal human peripheral
mononuclear cells (17, 40, 41).Taken together, these results support
that resveratrol is a proapoptotic agent in myeloma cells and can
work in synergy with other anticancer treatments.
In conclusion, our study shows that resveratrol has a unique set
of properties of interest for treatment of multiple myeloma
patients, especially with respect to its different actions on myeloma
cell growth, bone resorption, and bone formation. Our in vitro
findings justify further in vivo studies to evaluate treatment of
multiple myeloma with resveratrol or derivatives showing the same
set of properties. The intake of resveratrol during daily moderate
wine consumption (1.25 mg/glass of wine containing high
resveratrol concentration, 25 Amol/L) is likely too low to induce
in vivo the effects we observed in vitro (f0.02 mg/kg resveratrol
for a 70 kg person). However, it has been reported that a daily oral
administration of a dose as high as 20 mg/kg to rats for 28 days was
not harmful with respect to final body weight and growth rate of
animals, hematologic and biochemical variables, and histologic
examination of vital organs (42). Such high doses of resveratrol
showed significant chemopreventive and/or antitumor activities
in vivo in breast cancer (43), skin cancer (16), liver cancer (44),
colorectal and intestinal cancers (45, 46), lung cancer (47), and
neuroblastoma (48). Regarding the effects of resveratrol on bone
in vivo , two rat studies have shown that oral administration of
resveratrol to ovariectomized rats prevents decrease in bone femur
strength and increases epiphysis bone mineral density in the same
manner as the bisphosphonate alendronate (49, 50). There are thus
already in vivo studies suggesting, in accordance with our present
data, that resveratrol may prevent increased bone degradation by
osteoclasts or may stimulate compensative bone formation by
osteoblasts. Although resveratrol has proven to be effective in vivo ,
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several pharmacokinetic studies have reported that its concentra-
tion in the plasma is rather low after administration due to its
quick biotransformation into conjugate forms (51, 52). The
discrepancy between the concentrations of resveratrol required
for antitumor effects in vitro (between 10 and 100 Amol/L in most
in vitro studies) and the plasma levels found to be efficacious
in vivo has not found any explanation yet. It has been speculated
that resveratrol conjugates, especially resveratrol glucuronide,
which can peak up to 105 Amol/L in plasma, may contribute to
the overall pharmacologic activity (53). In addition, one should
mention that the gain of interest for resveratrol for cancer
treatment has encouraged the design and synthesis of resveratrol
derivatives more stable and 100-fold more potent than the native
molecule in inhibiting proliferation and inducing apoptosis in
cancer cell lines (54, 55). It would be of great interest to determine
whether these structural analogues act in the same manner on
bone cells.
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